Lucid Diagnostics Inc. Common Stock (LUCD)
Stock · NASDAQ · Health Care
$0.4806as of 10/16/2026
Price chart
Active signals
LUCD Signal Track Record
How signals performed across all stocks →What LUCD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -10.3% | 33% | October 1, 2026 |
| Bollinger Band Breakout | 22 | -5.2% | 36% | July 15, 2026 |
| Bollinger Band Breakdown | 20 | -5.4% | 30% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -7.6% | 31% | July 15, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since August 1, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 82
- Website
- www.luciddx.com/
Fundamentals
- 1-day range
- $0.51$0.5687
- Market cap
- $193.54M
- P/E (trailing)
- —
- P/E (forward)
- -3.15
- EPS (trailing)
- $-0.38
- Dividend yield
- —
- Beta
- 1.16
- Avg. volume
- 1.33M
How Lucid Diagnostics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Lucid Diagnostics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LUCDLucid Diagnostics Inc. Common Stock$0.478▼ 8.08%Market cap $193.54MP/E —$0.5$1.63
- EMBCEmbecta Corp. Common Stock$6.27▼ 2.79%Market cap $207.65MP/E 4.00$2.77$14.91
- PDEXPro-Dex Inc. Common Stock$58.26▼ 2.93%Market cap $209.06MP/E 14.11$23.47$77
- APYXApyx Medical Corporation Common Stock$2.55▼ 0.39%Market cap $174.35MP/E —$2.32$5.08
- SENSSenseonics Holdings Inc. Common Stock$7.77▼ 5.59%Market cap $215.29MP/E —$4.79$10.64
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3▼ 0.99%Market cap $163.52MP/E —$2.86$6.61
- CVRXCVRx Inc. Common Stock$1.3▼ 6.47%Market cap $157.62MP/E —$1.28$11.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LUCD Lucid Diagnostics Inc. Common Stock | $193.54M | — | $0.478 | ▼ 8.08% | $0.5$1.63 |
| EMBC Embecta Corp. Common Stock | $207.65M | 4.00 | $6.27 | ▼ 2.79% | $2.77$14.91 |
| PDEX Pro-Dex Inc. Common Stock | $209.06M | 14.11 | $58.26 | ▼ 2.93% | $23.47$77 |
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $2.55 | ▼ 0.39% | $2.32$5.08 |
| SENS Senseonics Holdings Inc. Common Stock | $215.29M | — | $7.77 | ▼ 5.59% | $4.79$10.64 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3 | ▼ 0.99% | $2.86$6.61 |
| CVRX CVRx Inc. Common Stock | $157.62M | — | $1.3 | ▼ 6.47% | $1.28$11.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- What's going on in today's after hours sessionChartMill · 10/1/2026
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 10/1/2026
- Which stocks are experiencing notable movement on Thursday?ChartMill · 10/1/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 10/1/2026
- Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysYahoo · 9/22/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 9/18/2026
Insider Activity
Insider Actions →- Dennis Matheis · May 20, 2026 · Buy245.0K @ $1
Institutional Ownership
March 31, 2026
- Total shares held
- 34.35M
- Total value held
- $39.39M
- Institutional holders
- 98
- Unknown4.64M
- Unknown4.15M
- Unknown4.00M
- Unknown3.64M
- Unknown3.00M
- Unknown2.25M
- Unknown1.58M
- Unknown1.55M
- Unknown1.27M
- Unknown1.13M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck
Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck. Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.